within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR06_EmtricitabineTenofovirDisoproxil;

model EmtricitabineTenofovirDisoproxil
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.76,
    Cl = 2.722222222222223e-06,
    adminDuration = 600,
    adminMass = 1100 / 1000000,
    adminCount = 1,
    Vd = 0.075,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.020833333333333332,
    Tlag = 10.200000000000001);

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>EmtricitabineTenofovirDisoproxilAndEfavirenz</td></tr><tr><td>ATC code:</td><td>J05AR06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>A fixed-dose combination of three antiretroviral medications: emtricitabine (a nucleoside reverse transcriptase inhibitor), tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor), and efavirenz (a non-nucleoside reverse transcriptase inhibitor). Used for the treatment of HIV-1 infection in adults and children and is currently approved for use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy HIV-negative adults receiving a single oral fixed-dose combination tablet (emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg, efavirenz 600 mg) under fasting conditions.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AR06 folded in (Drugs.ATC removed)</li><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end EmtricitabineTenofovirDisoproxil;
